首页> 美国卫生研究院文献>Neuro-oncology Advances >SL2 ADVANCES IN MOLECULAR BIOLOGY AND GENETICS IN GLIOMA RESEARCH AND THERAPY
【2h】

SL2 ADVANCES IN MOLECULAR BIOLOGY AND GENETICS IN GLIOMA RESEARCH AND THERAPY

机译:SL2在胶质瘤研究和治疗中的分子生物学和遗传学研究进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The most recent version of the includes, for the first time, the joint consideration of tumor pathology with tumor genetics as measured in various ways. This has come decades after the first recognition of genetic lesions in tumor genomes as discerned by cytogenetics and more than 30 years after the first reports of specific and recurrent genetic abnormalities in human tumors, particularly gliomas. This information is vitally important because it is now being used not just for tumor diagnosis but also to indicate specific therapies. In this lecture, I will review the increasingly precise methodologies being employed, the resultant genetic lesions being uncovered and the increasing import of such information for therapeutic selection.
机译:最新版本首次将肿瘤病理学与以各种方式测量的肿瘤遗传学共同考虑在内。这是在细胞遗传学首次认识到肿瘤基因组中的遗传损伤之后数十年,而在人类肿瘤特别是神经胶质瘤中首次出现特异性和复发性遗传异常的报道之后已有30多年了。该信息至关重要,因为该信息现在不仅用于肿瘤诊断,还用于指示特定的治疗方法。在本讲座中,我将回顾所采用的日益精确的方法,尚未发现的遗传病灶以及越来越多的此类信息用于治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号